文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

细胞毒性T淋巴细胞相关抗原4的转运与表面表达

CTLA-4 trafficking and surface expression.

作者信息

Valk Elke, Rudd Christopher E, Schneider Helga

机构信息

Cell Signalling Section, Department of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.

出版信息

Trends Immunol. 2008 Jun;29(6):272-9. doi: 10.1016/j.it.2008.02.011. Epub 2008 May 9.


DOI:10.1016/j.it.2008.02.011
PMID:18468488
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4186961/
Abstract

The T-cell co-receptor cytotoxic T-cell antigen 4 (CTLA-4) has a strong inhibitory role as shown by the lymphoproliferative phenotype of CTLA-4-deficient mice. Despite its potent effects on T-cell function, CTLA-4 is primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid internalisation. Recently, several signalling molecules such as Trim, PLD, ARF-1 and TIRC7 have been described to be involved in the transport of CTLA-4 to the cell surface. Minor changes in surface expression levels have major effects on the outcome of T-cell activation. Optimal regulation of CTLA-4 surface expression is crucial for the balance of stimulatory and inhibitory signals to maximize protective immune responses while maintaining immunological tolerance and preventing autoimmunity.

摘要

T细胞共受体细胞毒性T细胞抗原4(CTLA-4)具有很强的抑制作用,CTLA-4缺陷小鼠的淋巴细胞增殖表型就表明了这一点。尽管CTLA-4对T细胞功能有强大作用,但其主要是一种细胞内抗原,其表面表达通过限制转运至细胞表面和快速内化而受到严格调控。最近,已描述了几种信号分子,如TRIM、PLD、ARF-1和TIRC7参与CTLA-4向细胞表面的转运。表面表达水平的微小变化对T细胞活化的结果有重大影响。CTLA-4表面表达的最佳调节对于刺激和抑制信号的平衡至关重要,以在维持免疫耐受和预防自身免疫的同时最大化保护性免疫反应。

相似文献

[1]
CTLA-4 trafficking and surface expression.

Trends Immunol. 2008-6

[2]
CD28 and CTLA-4 coreceptor expression and signal transduction.

Immunol Rev. 2009-5

[3]
T cell receptor-interacting molecule acts as a chaperone to modulate surface expression of the CTLA-4 coreceptor.

Immunity. 2006-11

[4]
TIRC7 inhibits T cell proliferation by modulation of CTLA-4 expression.

J Immunol. 2006-11-15

[5]
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.

Immunol Rev. 2008-8

[6]
CTLA-4 co-receptor impacts on the function of Treg and CD8+ T-cell subsets.

Eur J Immunol. 2009-3

[7]
T-cell regulation by CD28 and CTLA-4.

Nat Rev Immunol. 2001-12

[8]
Human leukocyte antigen class I-restricted immunosuppression by human CD8+ regulatory T cells requires CTLA-4-mediated interaction with dendritic cells.

Hum Immunol. 2008-11

[9]
Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity.

Proc Natl Acad Sci U S A. 2010-1-4

[10]
Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation.

J Biol Chem. 2019-2-13

引用本文的文献

[1]
Negative Immune Checkpoint Inhibitors.

Pharmaceutics. 2025-5-28

[2]
Physiologically Based Pharmacokinetic Models for Infliximab, Ipilimumab, and Nivolumab Developed with GastroPlus to Predict Hepatic Concentrations.

Pharmaceutics. 2025-3-14

[3]
Role of lysine-specific demethylase 1 in immunotherapy of gastric cancer: An update.

Chin J Cancer Res. 2024-12-30

[4]
Identification of a novel molecular classification for hepatocellular carcinoma based on disulfideptosis-related genes and its potential prognostic significance.

J Cancer Res Clin Oncol. 2024-11-18

[5]
Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy.

Cancer Discov. 2024-12-2

[6]
Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy.

Cancers (Basel). 2024-5-24

[7]
CRP and soluble CTLA4 are determinants of anti-PD1 resistance in gastrointestinal cancer.

Am J Cancer Res. 2024-3-15

[8]
Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic Colorectal Cancer.

Medicina (Kaunas). 2024-2-26

[9]
Modern cancer therapy: cryoablation meets immune checkpoint blockade.

Front Oncol. 2024-2-7

[10]
Five Inhibitory Receptors Display Distinct Vesicular Distributions in Murine T Cells.

Cells. 2023-10-31

本文引用的文献

[1]
Differential inhibition of autoreactive memory- and alloreactive naive T cell responses by soluble cytotoxic T lymphocyte antigen 4 (sCTLA4), CTLA4Ig and LEA29Y.

Clin Exp Immunol. 2007-12

[2]
Enhanced engagement of CTLA-4 induces antigen-specific CD4+CD25+Foxp3+ and CD4+CD25- TGF-beta 1+ adaptive regulatory T cells.

J Immunol. 2007-10-15

[3]
Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter.

J Immunol. 2007-9-15

[4]
TIRC7 inhibits T cell proliferation by modulation of CTLA-4 expression.

J Immunol. 2006-11-15

[5]
T cell receptor-interacting molecule acts as a chaperone to modulate surface expression of the CTLA-4 coreceptor.

Immunity. 2006-11

[6]
Retrograde transport from endosomes to the trans-Golgi network.

Nat Rev Mol Cell Biol. 2006-8

[7]
Reversal of the TCR stop signal by CTLA-4.

Science. 2006-9-29

[8]
ARF proteins: roles in membrane traffic and beyond.

Nat Rev Mol Cell Biol. 2006-5

[9]
Normal T-cell development and immune functions in TRIM-deficient mice.

Mol Cell Biol. 2006-5

[10]
A molecular perspective of CTLA-4 function.

Annu Rev Immunol. 2006

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索